We have represented clients in the biotech field from the inception of law in this sector. Our experience extends from the earliest days, where the protection of specific nucleic acids and proteins still existed (e.g. HCV and HIV), to essay technologies, PCR technologies, antibodies and Next Generation Sequencing (NGS), vaccination technology and biological drugs, including biosimilars.